Literature DB >> 12379118

SCH28080, a K+-competitive inhibitor of the gastric H,K-ATPase, binds near the M5-6 luminal loop, preventing K+ access to the ion binding domain.

O Vagin1, S Denevich, K Munson, G Sachs.   

Abstract

Inhibition of the gastric H,K-ATPase by the imidazo[1,2-alpha]pyridine, SCH28080, is strictly competitive with respect to K+ or its surrogate, NH4+. The inhibitory kinetics [V(max), K(m,app)(NH4+), K(i)(SCH28080), and competitive, mixed, or noncompetitive] of mutants can define the inhibitor binding domain and the route to the ion binding region within M4-6. While mutations Y799F, Y802F, I803L, S806N, V807I (M5), L811V (M5-6), Y928H (M8), and Q905N (M7-8) had no effect on inhibitor kinetics, mutations P798C, Y802L, P810A, P810G, C813A or -S, I814V or -F, F818C, T823V (M5, M5-6, and M6), E914Q, F917Y, G918E, T929L, and F932L (M7-8 and M8) reduced the affinity for SCH28080 up to 10-fold without affecting the nature of the kinetics. In contrast, the L809F substitution in the loop between M5 and M6 resulted in an approximately 100-fold decrease in inhibitor affinity, and substitutions L809V, I816L, Y925F, and M937V (M5-6, M6, and M8) reduced the inhibitor affinity by 10-fold, all resulting in noncompetitive kinetics. The mutants L811F, Y922I, and I940A also reduced the inhibitor affinity up to 10-fold but resulted in mixed inhibition. The mutations I819L, Q923V, and Y925A also gave mixed inhibition but without a change in inhibitor affinity. These data, and the 9-fold loss of SCH28080 affinity in the C813T mutant, suggest that the binding domain for SCH28080 contains the surface between L809 in the M5-6 loop and C813 at the luminal end of M6, approximately two helical turns down from the ion binding region, where it blocks the normal ion access pathway. On the basis of a model of the Ca-ATPase in the E2 conformation (PDB entry 1kju), the mutants that change the nature of the kinetics are arranged on one side of M8 and on the adjacent side of the M5-6 loop and M6 itself. This suggests that mutations in this region modify the enzyme structure so that K+ can access the ion binding domain even with SCH28080 bound.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12379118     DOI: 10.1021/bi025921w

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  16 in total

1.  A chemical genetics approach reveals H,K-ATPase-mediated membrane voltage is required for planarian head regeneration.

Authors:  Wendy S Beane; Junji Morokuma; Dany S Adams; Michael Levin
Journal:  Chem Biol       Date:  2011-01-28

2.  Electrogenic partial reactions of the gastric H,K-ATPase.

Authors:  Anna Diller; Olga Vagin; George Sachs; Hans-Jürgen Apell
Journal:  Biophys J       Date:  2005-03-04       Impact factor: 4.033

Review 3.  Gastric H,K-ATPase as a drug target.

Authors:  Jai Moo Shin; George Sachs
Journal:  Dig Dis Sci       Date:  2006-04-28       Impact factor: 3.199

4.  Analysis of the gastric H,K ATPase for ion pathways and inhibitor binding sites.

Authors:  Keith Munson; Richard J Law; George Sachs
Journal:  Biochemistry       Date:  2007-04-11       Impact factor: 3.162

5.  Inter-subunit interaction of gastric H+,K+-ATPase prevents reverse reaction of the transport cycle.

Authors:  Kazuhiro Abe; Kazutoshi Tani; Tomohiro Nishizawa; Yoshinori Fujiyoshi
Journal:  EMBO J       Date:  2009-04-23       Impact factor: 11.598

6.  An ion gating mechanism of gastric H,K-ATPase based on molecular dynamics simulations.

Authors:  Richard J Law; Keith Munson; George Sachs; Felice C Lightstone
Journal:  Biophys J       Date:  2008-06-20       Impact factor: 4.033

Review 7.  Molecular mechanisms in therapy of acid-related diseases.

Authors:  J M Shin; O Vagin; K Munson; M Kidd; I M Modlin; G Sachs
Journal:  Cell Mol Life Sci       Date:  2008-01       Impact factor: 9.261

8.  The binding selectivity of vonoprazan (TAK-438) to the gastric H+, K+ -ATPase.

Authors:  D R Scott; K B Munson; E A Marcus; N W G Lambrecht; G Sachs
Journal:  Aliment Pharmacol Ther       Date:  2015-09-30       Impact factor: 8.171

9.  Characterization of a novel potassium-competitive acid blocker of the gastric H,K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438).

Authors:  Jai Moo Shin; Nobuhiro Inatomi; Keith Munson; David Strugatsky; Elmira Tokhtaeva; Olga Vagin; George Sachs
Journal:  J Pharmacol Exp Ther       Date:  2011-08-09       Impact factor: 4.030

Review 10.  The gastric HK-ATPase: structure, function, and inhibition.

Authors:  Jai Moo Shin; Keith Munson; Olga Vagin; George Sachs
Journal:  Pflugers Arch       Date:  2008-06-06       Impact factor: 3.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.